The global cancer immunotherapy market was valued at USD 153.31 billion in 2025 and is projected to reach USD 366.28 billion by 2035, growing at a robust CAGR of 9.10%. This growth is driven by innovative therapies and increased demand for advanced cancer treatments, offering new hope in cancer care.
Cancer Immunotherapy Market Statical Scope
| Reports Attributes |
Statistics |
| Market Size in 2025 |
USD 153.31 Billion |
| Market Size in 2026 |
USD 167.26 Billion |
| Market Size in 2032 |
USD 282.06 Billion |
| Market Size by 2035 |
USD 366.28 Billion |
| CAGR 2026 to 2035 |
9.10% |
| Base Year |
2025 |
| Forecast Period |
2026 to 2035 |
Cancer immunotherapy is one of the most popular treatment types, spurring growth in the oncology sector. The unique discussion topic of this treatment is the procedure involving an individual's own immune system participation to spot and eliminate the cancer cells before they reach severity.
The immunotherapy has its own specialization, advanced, harmless power which only focuses on either training or fuelling up one’s own natural shield available and effective. It leaves no chance for a halt at a longer and more painful treatment, but itself finds the potential to stop the prone proteins from communicating with cancer cells.
The famous CAR T-cell therapy, cancer vaccines, and oncolytic viruses are bringing this market to the limelight in the oncology field. There’s a wide business growth for this market as the demand for targeted therapies and innovation in next-gen therapies is skyrocketing with the growing number of cancer cases. Industry leaders, alliances, and heavy R&D investments are paving the way for business opportunities and the development of innovative therapies in the market.
Furthermore, the dominance of monoclonal antibodies has helped the market expand its footprint in the R&D space like never before.
Cancer Immunotherapy Market Share, By Region, 2025 (%)
| Regions |
Shares (%) |
| North America |
12.95% |
| Europe |
16.06% |
| Asia-Pacific |
30.92% |
| Latin America |
17.46% |
| Middle East & Africa |
22.61% |
- North America – The leadership quality in North America's healthcare sector, with the highest rapid adoption rate of new technologies, ensures exponential use of investments at the right place, complying with the FDA’s regulatory policies.
- Europe – Europe’s smart attentiveness in the foundational research for vast clinical applications, with the valuable contribution of oncology-based startups, is forming a strong base of precision for cancer immunotherapy.
- Asia-Pacific – Asia Pacific’s cancer immunotherapy sector is highly encouraged due to rising cancer conditions, eventually turning into a heavy clinical expansion rate. With the regulatory support and sincere inspection of new medication/drug approval, the regional market tends to acquire an effective share.
- Latin America – Latin America has acquired the best of the substantial growth in this market with its intelligent clinical trial hub and advanced regulatory body, which is strengthening the drug discovery and development area, mainly for innovative therapies.
- Middle East & Africa – The active participation and growing engagements among regional market leaders with the intelligent blend of popular trends of AI and precision medicine. The new collaborations are unlocking innovative solutions in this market.
Cancer Immunotherapy Market Share, By Product, 2025 (%)
| Segments |
Shares (%) |
| Monoclonal Antibodies |
53% |
| Immunomodulator |
44.34% |
| Oncolytic Viral Therapies and Cancer Vaccines |
18.76% |
- Monoclonal Antibodies – The monoclonal antibodies product is a fundamental part and power of advanced cancer immunotherapy. The segment's involvement in this market via impressive modernization in genetic engineering brings more weightage to the segmental growth.
- Immunomodulators – The immunomodulators hold the diversified modalities ranging from small molecule-related immunomodulators to natural/organic products to help the tumor turn hot. While the smart stimuli-responsive nanomodulators promote nanotechnology in this market segment.
- Oncolytic Viral Therapies and Cancer Vaccines – The segment tends to grow with its tumor cell killing potential, promoting the amalgamation of checkpoint inhibitors for more efficacy in treatment.
Cancer Immunotherapy Market Share, By Application, 2025 (%)
| Segments |
Shares (%) |
| Lung Cancer |
1.07% |
| Breast Cancer |
0.16% |
| Melanoma |
98.77% |
- Lung Cancer – Lung cancer cases are pushing the cancer immunotherapy sector to transition to personalized medicine and care for long-term impact on the overall health condition, mainly in NSCLC.
- Breast Cancer – Breast cancer condition is seen to be rising, which has broadened the treatment and introduced a shift in patient care, especially for TNBC, commonly with the help of pembrolizumab. The full-fledged support of advanced therapies aligns with the future development of medication.
- Melanoma – Melanoma is steadily acquiring the average share in this market, with the transition observed in the oncology sector from chemotherapy to personalized vaccines volume, combination therapies, and ICIs
Cancer Immunotherapy Market Share, By Distribution Channel, 2025 (%)
| Segments |
Shares (%) |
| Hospital Pharmacy |
53.16% |
| Retail Pharmacy |
16.23% |
| Online Pharmacy |
30.61% |
- Hospital Pharmacy – The hospital pharmacy segment is increasingly moving to the forefront for effective drug accessibility to meet patients' needs for advanced targeted therapies and medications. With the growing responsibility in the critical biologics task, the requirement for specialized pharmacy staff has also increased.
- Retail Pharmacy – The retail pharmacy segment holds an effective share in the market with extensive outpatient immunotherapy treatments for better patient access, providing comfort with self-care and administration rights.
- Online Pharmacy – The online pharmacy is a popular distribution channel for doorstep delivery, mainly in emergency cases. The branded drug accessibility acts as a short-term relief for the patients.
Cancer Immunotherapy Market Share, By End-use, 2025 (%)
| Segments |
Shares (%) |
| Hospitals and Clinics |
31.16% |
| Cancer Research Centers |
14.63% |
| Others |
54.21% |
- Hospitals and Clinics – The segment growth is measured by the development and adoption of modern cell-based therapies and robust cold chain logistics facilities to manage the immunotherapy procedure and services.
- Cancer Research Centers – The oncology sector is emerging as a commendable cooperative sector, maintaining internal workflow with higher precision through teamwork. The heavy investments in research boost the clinical trials and research part.
- Others – The specialized clinics and cancer research institutes, a few in alliance with the government, are introducing massive translational research and sharpening clinical infrastructure to emerge as a valuable contributor to this market.
